Hikma Pharmaceuticals PLC, a London-based, multinational pharmaceutical company, announced on Thursday that it has extended the shelf-life of KLOXXADO (naloxone HCl) nasal spray eight mg from 24 to 36 months.

The product's packaging has been updated with 36-month dating, starting with product manufactured in March 2024.

KLOXXADO includes twice as much naloxone per spray as Narcan Nasal Spray four mg in a ready-to-use nasal spray to reverse the impact of opioid overdose, providing a treatment option in dealing with the overdose epidemic.

Dr Hafrun Fridriksdottir, president, Hikma Generics, said, 'The shelf-life extension is good news for frontline responders and the thousands of people who carry KLOXXADO and who may need to use it at a moment's notice to reverse an overdose. We have a role to play in the fight against illicit fentanyl and as we approach International Overdose Awareness Day on 31 August, it's gratifying that we are supplying an important medicine that can save lives and help address the deadly overdose epidemic.'